BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 09, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mipomersen: Phase III data

A double-blind, international Phase III trial in 58 patients with severe hypercholesterolemia showed that once-weekly subcutaneous injections of 200 mg mipomersen for 26 weeks met the primary endpoint of significantly reducing LDL-C from baseline to week 28 vs. placebo (36% reduction vs. 13% increase, p<0.001). Specifically, mipomersen reduced LDL-C from an average of 276 mg/dL at baseline to 175 mg/dL at week 28. Mipomersen also...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >